Company Announcement no. 2/2012
To: NASDAQ OMX Copenhagen A/S Hørsholm, Denmark, January 25, 2012
Veloxis Pharmaceuticals Announces Financial Calendar for 2012
Veloxis Pharmaceuticals A/S (OMX: VELO) today announced financial calendar for 2012.
7. March, 2012: Release of Annual Report 2011.
18 April, 2012: Annual General Meeting.
15 May, 2012: Interim Report for the 1st Quarter ‐ for the period 1 January to 31 March, 2012.
22 August, 2012: Interim Report for the 2nd Quarter – for the period 1 January to 30 June, 2012.
14 November, 2012: Interim Report for the 3rd Quarter – for the period 1 January to 30 September, 2012.
For more information, please contact:
Veloxis Pharmaceuticals A/S
Johnny Stilou William J. Polvino
CFO President & CEO
Phone: (+45) 21 227 227 Phone: (+1) 732 321 3202
Email: jst@veloxis.com Email: wjp@veloxis.com
About Veloxis Pharmaceuticals
Based in Hørsholm, Denmark, with an office in New Jersey, Veloxis Pharmaceuticals A/S, or Veloxis, is a specialty pharmaceutical company. Clinical development is the core of Veloxis’ efforts to develop a product portfolio which includes the Company’s lead product candidate, LCP‐Tacro™, for immunosuppression, specifically organ transplantation, and products to combat certain cardiovascular diseases. Veloxis adapts new technologies on a fast commercial timetable. Veloxis’ unique, patented delivery technology, MeltDose®, can improve absorption and bioavailability ‐ at low‐scale up costs ‐ not only for a broad spectrum of drugs already on the market but also for new chemical entities. Veloxis has a lipid lowering product, Fenoglide®, currently on the U.S. market and a diversified near and medium term pipeline with three clinical stage product candidates and a number of projects in preclinical development. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.
For further information, please visit www.veloxis.com.
